Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

Secretary of the Senate Received: Feb 13, 2008

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name: WILLIAMS & JENSEN 1155 Twenty-First Street, N.W. Suite 300, Washington, DC 20036 3. Principal place of business (if different from line 2): 4. Contact Name: WILLIAM B. CANFIELD Telephone: 2026598201 E-mail (optional): wbcanfield@wms-jen.com Senate ID #: 41454-645 House ID #: 7. Client Name: Self PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA TYPE OF REPORT __ Midyear (January 1 - June 30): 🔲 OR Year End (July 1 - December 31): 🔀 9. Check if this filing amends a previously filed version of this report: 10. Check if this is a Termination Report:

=> Termination Date: 11. No Lobbying Activity: INCOME OR EXPENSES Complete Either Line 12 OR Line 13 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000: -\$10,000 or more: X => Income (nearest \$20,000): 120,000.00 Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000: -\$10,000 or more: => Expenses (nearest \$20,000); 14. Reporting Method. Check box to indicate expense accounting method. See instructions for description of options. Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Page 1

Registrant Name: WILLIAMS & JENSEN Client Name: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: HCR (one per page)
- 16. Specific lobbying issues:

Prescription Drug user Fees; Drug Safety/Clinical Trials; Pediatric Trials and Studies; Drug Importation and Counterfeiting; Drug Advertising; Follow-On Biologics; s. 2029; competitive effectiveness; e-prescribing.

17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BEER, MICHAEL Covered Official Position (if applicable): N/A Name: CANFIELD, WILLIAM Covered Official Position (if applicable): N/A Name: CARP, BERTRAM Covered Official Position (if applicable): N/A Name: DIJAMES, JENNY Covered Official Position (if applicable): N/A Name: DWYER, DENIS Covered Official Position (if applicable): N/A Name: HART, J STEVEN Covered Official Position (if applicable): N/A Name: HIRSCHMANN, SUŠAN Covered Official Position (if applicable): N/A Name: LYNCH, KARINA Covered Official Position (if applicable): N/A Name: OLSEN, GEORGE Covered Official Position (if applicable): N/A Name: ROGERS, JOYCE A Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Registrant Name: WILLIAMS & JENSEN Client Name: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: MMM (one per page)
- 16. Specific lobbying issues:

Medicare Prescription Drug Benefit; Medicare drug rebate; drug price negotiation; Medicare drug coverage and payment.

17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DIJAMES, JENNY
Covered Official Position (if applicable): N/A
Name: LYNCH, KARINA
Covered Official Position (if applicable): N/A
Name: OLSEN, GEORGE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Signature: ON FILE Date: Feb 13, 2008

Printed Name and Title: M. KELLEY -

Registrant Name: WILLIAMS & JENSEN Client Name: PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Feb 13, 2008

Printed Name and Title: -